LI Peng,ZHANG Yuanyuan,ZHANG Haoran,et al.Multi-scale Mechanisms of Maxing Shigantang in Treating Pneumonia Based on Transcriptomic Data[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(01):82-90.
LI Peng,ZHANG Yuanyuan,ZHANG Haoran,et al.Multi-scale Mechanisms of Maxing Shigantang in Treating Pneumonia Based on Transcriptomic Data[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(01):82-90. DOI: 10.13422/j.cnki.syfjx.20221417.
Multi-scale Mechanisms of Maxing Shigantang in Treating Pneumonia Based on Transcriptomic Data增强出版
Pneumonia is an infectious inflammation of the alveoli, distal airway, and interstitium caused by bacterial, viral, and other pathogens. Maxing Shigantang, originated from
Treatise On Cold Damage Diseases
, is a classic prescription for treating pneumonia, with significant clinical efficacy. However, its treatment mechanism is still elusive.
Method
2
In that paper, the transcriptome-based multi-scale network pharmacology was used to reveal the overall pharmacological mechanism of Maxing Shigantang in treating pneumonia from six scales of tissue, cell, pathological process, biological process, signaling pathway, and target.
Result
2
At the tissue level, Maxing Shigantang mainly acted on the focal tissue of pneumonia-lung and the main inflammatory immune tissues-blood and spleen. Analysis of cell, pathological process and biological process suggested that Maxing Shigantang could treat pneumonia by reversing inflammatory and immune functions and improving cardiopulmonary and vascular injury caused by pneumonia. Analysis of signaling pathway and target showed that Maxing Shigantang regulated inflammatory immune response pathways such as "coronavirus disease-COVID-19" and "Toll-like receptor signaling pathway", and related targets such as "MAPKAPK3" and "NRG1".
Conclusion
2
This paper, from molecular to tissue levels, indicated Maxing Shigantang treated pneumonia mainly by regulating inflammatory immune response and improving cardiopulmonary and vascular injury.
HSIEH C F , LO C W , LIU C H , et al . Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus [J]. J Ethnopharmacol , 2012 , 143 ( 1 ): 57 - 67 .
LI S , ZHANG B . Traditional Chinese medicine network pharmacology: Theory, methodology and application [J]. Chin J Nat Med , 2013 , 11 ( 2 ): 110 - 120 .
LI P , ZHANG H , ZHANG W , et al . TMNP:A transcriptome-based multi-scale network pharmacology platform for herbal medicine [J]. Brief Bioinform , 2022 , doi: 10.1093/bib/bbab542 http://dx.doi.org/10.1093/bib/bbab542 .
LI Q , BAI C , YANG R , et al . Deciphering the pharmacological mechanisms of Ma Xing Shi Gan decoction against COVID-19 through integrating network pharmacology and experimental exploration [J]. Front Pharmacol , 2020 , 11 : 581691 .
ZHANG X , LAN Y , XU J , et al . CellMarker:A manually curated resource of cell markers in human and mouse [J]. Nucleic Acids Res , 2019 , 47 ( D1 ): D721 - D728 .
ZHU Q , WONG A K , KRISHNAN A , et al . Targeted exploration and analysis of large cross-platform human transcriptomic compendia [J]. Nat Methods , 2015 , 12 ( 3 ): 211 - 214 .
SUBRAMANIAN A , NARAYAN R , CORSELLO S M , et al . A next generation connectivity map:L1000 platform and the first 1,000,000 profiles [J]. Cell , 2017 , 171 ( 6 ): 1437 - 1452 .
YANG Z , ZOU X , FENG P , et al . Inhibition of the PI3K/Akt signaling pathway or overexpression of beclin1 blocks reinfection of Streptococcus pneumoniae after infection of influenza a virus in severe community-acquired pneumonia [J]. Inflammation , 2019 , 42 ( 5 ): 1741 - 1753 .
XIAO J , LI B , ZHENG Z , et al . Therapeutic effects of neuregulin-1 gene transduction in rats with myocardial infarction [J]. Coron Artery Dis , 2012 , 23 ( 7 ): 460 - 468 .